I find it interesting regarding the "timing" of today's PR,
exactly at the opening bell at 9:30 A.M.

I don't have any answers but I am open to thoughts as to what
the strategy was behind it.Mgt.has been very selective in the
timing lately so there must be a reason.

Also of interest is the reinforcement of the company's plans
when the "funding" arrives.

Per the PR:

"As we continue to advance the clinical development of our Brilacidin
programs in Oral Mucositis and Inflammatory Bowel Disease, the Company
concurrently plans to devote resources to Kevetrin, including completing
remaining bridging toxicology work toward developing Kevetrin in oral form.
An orally-delivered Kevetrin would likely enhance the therapeutic benefits
based on its pharmacokinetics, and broaden its market potential by meeting
cancer patient’s strong preference for oral meds."

If there IS a "suitor" who has been aiding IPIX lately in Europe,I find it
difficult to think that there is a "bidding war"going on at the same time.
(Why help IPIX and lose the bidding war and wind up with nothing?)

There MUST be more going on than meets the eye.

Kelt